CHICAGO, July 14, 2015 /PRNewswire/ -- Analyte Health is pleased to announce Dr. Frank Cockerill as the digital health company's next Chief Executive Officer. Dr. Cockerill recently completed his second term as Chair of Department of Laboratory Medicine and Pathology, Mayo Clinic, and President and CEO of Mayo Collaborative Services, Inc., the largest for-profit company associated with Mayo Clinic and the third largest provider of diagnostic laboratory services in the United States, serving more than 4,000 clients in 130 countries.
"As Analyte Health positions itself for growth, the Board is confident that Frank Cockerill is the right person to take the company to the next level," said Phyllis Whiteley, PhD., Board Director and Venture Partner with Mohr Davidow Ventures. "He has a proven ability to drive strategic clarity and innovation, ensure operational excellence, and deliver outstanding results. We believe that his passion and experience will guide Analyte Health to expand its reach and elevate its focus on early disease detection and prevention for health consumers."
"It is a tremendous privilege to be chosen to lead Analyte Health at this important turning point in the company's history," said Dr. Cockerill. "We are uniquely positioned to activate health consumers and bridge gaps in care in a very meaningful way."
Dr. Frank Cockerill is Board Certified in Internal Medicine and Infectious Diseases and Clinical Microbiology. He has held various industry, professional society and government leadership positions with the FDA, CDC, American Clinical Laboratory Association Board and others. In addition, Dr. Cockerill was the Editor of the Journal of Clinical Microbiology. His research in developing real-time PCR assays has resulted in eight U.S. patents, two foreign patents and 56 licensed technologies.
Read more about Analyte Health here: http://www.analytehealth.com/about-us/
About Analyte Health, Inc.
Analyte Health is a consumer-centric patient acquisition and digital healthcare delivery company. Its mission is to provide convenient access to education, navigation, diagnostic testing, personalized results and recommendations to consumers through its digital clinics. Analyte Health offers access via the phone and the web to a national team of doctors and partner diagnostic labs. Over 250,000 patients have trusted Analyte Health to deliver convenient and private STI testing and treatment. More information about the company is available at http://www.AnalyteHealth.com.
Analyte Health, Inc. is a privately held company. This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits to consumers from using Analyte Health's services. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of risks and uncertainties, including, among other things, the potential impact of regulatory and third party payer developments in the field of telehealth and STI testing, general business and economic conditions, changes in arrangements with vendors or suppliers, and costs or delays in obtaining or maintaining regulatory approvals and licenses. Any forward-looking statements in this release are based on limited information currently available to Analyte Health, which is subject to change, and Analyte Health will not necessarily update the information.
CONTACT: Michelle Sobel, 708-602-2607, firstname.lastname@example.org
SOURCE Analyte Health, Inc.